First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS (TRIPLETE)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03231722 |
Recruitment Status :
Completed
First Posted : July 27, 2017
Last Update Posted : January 5, 2023
|
Sponsor:
Gruppo Oncologico del Nord-Ovest
Information provided by (Responsible Party):
Gruppo Oncologico del Nord-Ovest
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | June 15, 2022 |
Actual Study Completion Date : | June 24, 2022 |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):